All Stories

  1. Epigenetic treatment approach and biomarkers for anti-HER2 resistance breast cancer treatment.

    Article • Proceedings of the National Academy of Sciences, July 2022, Proceedings of the National Academy of Sciences

    Li Teng Ong

  2. HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment

    Article • Cell Cycle, June 2019, Taylor & Francis

    Li Teng Ong